The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...
"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...
The Greek director of the positron emission tomography (PET/CT) scanner at the DFKZ research centre in Heidelberg talks about ...
A VISION-like, Single-Center Analysis Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer PSMA-Directed ...
The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.
The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...
The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback